Neurocrine Biosciences paid its one named executive on file $16.0M in FY2024 (Dec).
Pay$100 in the stock at the end of FY19 → $123
Pay of each named executive
| FY2023 (Dec) | |||||||
| FY2022 (Dec) | Not disclosed | ||||||
| FY2021 (Dec) | Not disclosed |
3 years
Sanjay Keswani, M.D.Chief Medical Officer Jude Onyia, Ph.D.
| FY2023 (Dec) | Not disclosed |
1 year
Matthew C. AbernethyChief Financial Officer
| FY2023 (Dec) | |||||||
| FY2022 (Dec) | Not disclosed | ||||||
| FY2021 (Dec) | Not disclosed | ||||||
| FY2020 (Dec) | Not disclosed |
4 years
Kyle W. Gano, Ph.D.Chief Executive Officer
| FY2023 (Dec) | |||||||
| FY2022 (Dec) | Not disclosed | ||||||
| FY2021 (Dec) | Not disclosed | ||||||
| FY2020 (Dec) | Not disclosed |
4 years
Eric BenevichChief Commercial Officer
| FY2022 (Dec) | Low confidence | Not disclosed |
1 year
CEO pay against the pay peers
In FY2022 (Dec), the median CEO pay of the 1 peer with pay on file was $16.7M. The CEO of Neurocrine Biosciences was paid $11.9M, 29% below the median.
- 1Incyte
- 2Neurocrine BiosciencesThis company
- 3ACADIA Pharmaceuticals, Inc.Not disclosed
- 4Alexion Pharmaceuticals, Inc.Not disclosed
- 5Alkermes plcNot disclosed
- 6Alnylam Pharmaceuticals, Inc.Not disclosed
- 7BeiGene, Ltd.Not disclosed
- 8BioMarin Pharmaceuticals, Inc.Not disclosed
- 9Biohaven Ltd.Not disclosed
- 10Exelixis, Inc.Not disclosed
- 11Horizon Therapeutics plcNot disclosed
- 12Ionis Pharmaceuticals, Inc.Not disclosed
- 13Jazz Pharmaceuticals plcNot disclosed
- 14Mirati Therapeutics, Inc.Not disclosed
- 15Nektar TherapeuticsNot disclosed
- 16Sarepta Therapeutics, Inc.Not disclosed
- 17Seagen Inc.Not disclosed
- 18Ultragenyx Pharmaceutical Inc.Not disclosed
- 19United Therapeutics CorporationNot disclosed
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.